Annual Report And Accounts

Overview

The report presents Arecor as a clinical-stage biotech focused on diabetes, obesity and other cardiometabolic diseases. It highlights the 2025 AT278 co-development partnership with Sequel and the Ligand royalty-financing transaction. Financial highlights include £3.1m of total revenue including discontinued operations and £6.1m of cash and cash equivalents.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2025
Period: Ends 31 December 2025
Language: English
Pages
File size
Restatement: Disclosed

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services